Fresenius SE & Co KGaA (FRA:FRE) Given a €51.00 Price Target by Barclays Analysts

Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €51.00 ($59.30) target price by equities researchers at Barclays in a note issued to investors on Friday, Borsen Zeitung reports. The brokerage currently has a “neutral” rating on the stock. Barclays‘s price objective would indicate a potential upside of 17.61% from the stock’s previous close.

Several other research analysts have also recently issued reports on the company. Warburg Research set a €65.00 ($75.58) target price on Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Friday, July 26th. HSBC set a €52.00 ($60.47) target price on Fresenius SE & Co KGaA and gave the company a “neutral” rating in a research report on Thursday. Berenberg Bank set a €74.80 ($86.98) target price on Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Monday, August 12th. Independent Research set a €51.00 ($59.30) target price on Fresenius SE & Co KGaA and gave the company a “neutral” rating in a research report on Friday, August 2nd. Finally, DZ Bank reaffirmed a “buy” rating on shares of Fresenius SE & Co KGaA in a research report on Wednesday, July 31st. Nine equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of €57.93 ($67.36).

Shares of FRA:FRE opened at €43.37 ($50.42) on Friday. Fresenius SE & Co KGaA has a 12-month low of €60.16 ($69.95) and a 12-month high of €80.00 ($93.02). The business’s 50 day moving average is €43.63 and its 200 day moving average is €46.49.

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Recommended Story: High-Yield Dividend Stocks

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.